| Literature DB >> 35498578 |
Chunmei Chen1,2, Huaming Tao3, Weihao Chen1,2, Bin Yang1, Xuefeng Zhou1, Xiaowei Luo4, Yonghong Liu1,4,2,5.
Abstract
Azaphilones have continuously aroused considerable attention owing to their structural diversity and significant biological activities recently. This review attempts to give a comprehensive summary of recent progress on the isolation, identification, and biological activity, along with synthetic and biosynthetic studies of azaphilones reported from October 2012 to December 2019. Herein, a total of 252 compounds predominantly originated from 32 genera of fungi, such as Penicillium (20%) and Talaromyces (11%), were included in this research with citations of 105 references. Among these azaphilones, approximately half of them were found with various biological activities, of which over 40% displayed cytotoxic/anti-tumor effects. This review would shed light on the future development and research of azaphilones. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35498578 PMCID: PMC9050426 DOI: 10.1039/d0ra00894j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Structural patterns of 13 types of azaphilones.
Fig. 2Chemical structures of citrinin-type azaphilones (1–27).
The sources and biological activities of recently reported azaphilones (1–252)
| No. | Species | Activity |
|---|---|---|
| Annulohypoxylomans A–C (1–3) |
| |
| Annulohypoxylomanols A–B (4–5) |
| |
| Annulohypoxyloside (6) |
| |
| 7 |
| |
| (3 |
| Cytotoxic (L5178Y: 26.20% at 10 μg mL−1) |
| (3 |
| Cytotoxic (L5178Y: 16.10% at 10 μg mL−1) |
| ( |
| Cytotoxic (MV4-11: 38.39 μM) |
| ( |
| |
| 8-Methoxy-3-methylisochromane-3,6-diol (12) |
| Cytotoxic (MV4-11: 30.00 μM) |
| 3,8-Dimethoxy-3-methylisochroman-6-ol (13) |
| |
| 3,6,7,8-Tetramethoxy-3-methylisochromane (14) |
| |
| Colletobredin A (15) |
| Anti-inflammatory (inhibit NO production: 182.2 μM) |
| Colletobredins B–D (16–18) |
| |
| Monascuspilorin (19) |
| |
| Monascupurpurin (20) |
| |
| Peyronellone A (21) |
| Antioxidant (ABTS: 88.8 μM, DPPH: 126.3 μM) |
| Peyronellone B (22) |
| Antioxidant (ABTS: 95.2 μM, DPPH: 83.5 μM); hypoxia-protective activity (improved the survival rate of H/R-treated human umbilical vein endothelial cells from 35% to 70% at 5 μM) |
| Penicitol A (23) |
| Cytotoxic (HeLa: 4.6 μM, BEL-7402: 10.5 μM, HEK-293: 6.7 μM, HCT-116: 5.6 μM, A549: 7.6 μM) |
| Citrifuran A (24) |
| Anti-inflammatory (inhibit NO production: 18.3 μM) |
| Citrifuran B (25) |
| Anti-inflammatory (inhibit NO production: 22.6 μM) |
| Citrifuran C (26) |
| Anti-inflammatory (inhibit NO production: 25.3 μM) |
| Citrifuran D (27) |
| |
| Fusaraisochromenone (28) |
| |
| Felinone A (29) |
| Brine shrimp toxic (61.4% at 100 μg mL−1) |
| Xylariphilone (30) |
| Anti-inflammatory (inhibit NO production: 17.5 μM,[ |
| Aspergillusone C (31) |
| Cytotoxic (MCF-7: 2.5 μM, A549: 41.9 μM) |
| 7( |
| |
| Chlamyphilone (33) |
| Insecticidal ( |
| Nemanecins A–C (34–36) |
| |
| Perangustols A–B (37–38) |
| |
| Dothideomynone C (40) |
| Cytotoxic (A549: 46.5 μg mL−1, HuCCA-1: 48.1 μg mL−1, MOLT-3: 17.4 μg mL−1) |
| Dothideomynones B (39), D–F (41–43) |
| |
| Mycoleptone A (44) |
| Cytotoxic (PC3: 10.0 μM); antileishmanial ( |
| Mycoleptone B (45) |
| Cytotoxic (PC3: 7.1 μM); antileishmanial ( |
| Mycoleptone C (46) |
| |
| Deflectin C1 (47) |
| Inhibit enzyme (SHP2: 29.3 μM, PTP1B: 40.4 μM) |
| Deflectin C2 (48) |
| Inhibit enzyme (SHP2: 21.1 μM, PTP1B: 19.8 μM) |
| Deflectin C3 (49) |
| Inhibit enzyme (SHP2: 16.2 μM, PTP1B: 16.5 μM) |
| Deflectin D1 (50) |
| Inhibit enzyme (SHP2: 19.2 μM, PTP1B: 19.2 μM) |
| Deflectin D2 (51) |
| Inhibit enzyme (SHP2: 7.0 μM, PTP1B: 6.1 μM) |
| Deflectin E (52) |
| Inhibit enzyme (SHP2: 16.0 μM, PTP1B: 24.0 μM) |
| 8,11-Didehydrochermesinone B (53) |
| |
| Colletotrichone A (54) |
| Antimicrobial ( |
| Colletotrichone B (55) |
| Antimicrobial ( |
| Colletotrichone C (56) |
| Antimicrobial ( |
| Coniellin A (57) |
| Anti-tumor (MDA-MB-231: 21.5 μM, inhibit NF-κB activation: 4.4 μM) |
| Coniellin B (58) |
| Anti-tumor (MDA-MB-231: 19.6 μM) |
| Coniellin C (59) |
| Anti-tumor (MDA-MB-231: 21.0 μM) |
| Coniellin D (60) |
| Anti-tumor (MDA-MB-231: 18.6 μM, inhibit NF-κB activation: 37.8 μM) |
| Coniellin E (61) |
| Anti-tumor (MDA-MB-231: 79.3 μM, inhibit NF-κB activation: 29.4 μM) |
| Coniellin F (62) |
| Anti-tumor (inhibit NF-κB activation: 70.7 μM) |
| Coniellin G (63) |
| Anti-tumor (MDA-MB-231: 21.6 μM, inhibit NF-κB activation: 11.3 μM) |
| Coniellins H–I (64–65) |
| |
| 5′,6′-Dihydroxyacetosellin (66) |
| |
| Monakaocinol (67) |
| |
| Monascuspirolide A (68) |
| Anti-inflammatory (inhibit NO production: 17.5 μM) |
| Monascuspirolide B (69) |
| Anti-inflammatory (inhibit NO production: 23.5 μM) |
| Thielavialides A–E (70–74) |
| |
| 5- |
| |
| 5- |
| |
| Peniazaphilin A (77) |
| Antiviral (HIV: 60.4 μM) |
| Monapilosusazaphilone (78) |
| |
| Monascusazaphilone A (79) |
| Anti-inflammatory (inhibit NO production: 4.6 μg mL−1); cytotoxic (LPS-induced RAW264.7: cell viability 83%) |
| Monascusazaphilone B (80) |
| Anti-inflammatory (inhibit NO production: 8.88 μg mL−1); cytotoxic (LPS-induced RAW264.7: cell viability 85%) |
| Berkchaetoazaphilone C (81) |
| |
| Monascuskaodione (82) |
| |
| Monascuspurone (83) |
| |
| Monasfluol B (84) |
| |
| Monascusazaphilone C (85) |
| Anti-inflammatory (inhibit NO production: 6.77 μg mL−1); cytotoxic (LPS-induced RAW264.7: cell viability 86%) |
| Acetyl-monasfluol B (86) |
| |
| MC-2, MC-4 (87–88) |
| |
| Berkchaetoazaphilone A (89) |
| Anti-tumor (inhibit TNF-α production: 95% at 100 μM, inhibit IL-1β production: 95% at 100 μM); anti-inflammatory (inhibit IL-6 production: 100% at 100 μM, inhibit IL-33 production: 100% at 100 μM); inhibit enzyme (caspase 1: 150 μM, MMP-3: 130 μM) |
| Berkchaetoazaphilone B (90) |
| Cytotoxic (Y79: 1.1 μM, MOLT-4: 10 μM, RPMI-8226: 10 μM, SR: 10 μM, LOX IMVI: 10 μM, CCRF-CEM: 10 μM); anti-tumor (inhibit TNF-α production: 95% at 100 μM, inhibit IL-1β production: 95% at 100 μM); anti-inflammatory (inhibit IL-6 production: 100% at 100 μM, inhibit IL-33 production: 100% at 100 μM); inhibit enzyme (caspase 1: 25 μM, MMP-3: 15 μM) |
| Lenormandin A (91) |
| Antimicrobial ( |
| Lenormandin B (92) |
| Cytotoxic (L929: 18.0 μg mL−1); antimicrobial ( |
| Lenormandin C (93) |
| Cytotoxic (L929: 32.0 μg mL−1); antimicrobial ( |
| Lenormandin D (94) |
| Antimicrobial ( |
| Lenormandin E (95) |
| Cytotoxic (L929: 22.0 μg mL−1); antimicrobial ( |
| Peyronellone F (96) |
| |
| Lenormandin F (97) |
| Antimicrobial ( |
| Lenormandin G (98) |
| Antimicrobial ( |
| Phialomustin A (99) |
| Cytotoxic (MIAPaCa2: 35 μM, A549: 98 μM, HCT-116: 8 μM, T47D: 10 μM) |
| Phialomustin C (100) |
| Cytotoxic (MIAPaCa2: 38 μM, HCT-116: 100 μM, T47D: 7 μM); antimicrobial ( |
| Phialomustin D (101) |
| Cytotoxic (MIAPaCa2: 60 μM, HCT-116: 30 μM, T47D: 9.2 μM); antimicrobial ( |
| Fragirubrins A–E (102–106) |
| |
| (+)-6′′-Hydroxymitorubrinol acetate (107) |
| Cytotoxic (L929: 21 μg mL−1) |
| (+)-6′′-Hydroxymitorubrinol (108) |
| |
| 6′′-Hydroxy-( |
| |
| Purpurquinone D (110) |
| |
| Talarophilones A–B (111–112) |
| |
| Pinophilins D–F (113–115) |
| |
| Rutilins C–D (116–117) |
| |
| Pinazaphilone A (118) |
| |
| Montagnuphilone B (120) |
| Anti-inflammatory (inhibit NO production: 39.58 μM) |
| Montagnuphilones A (119), C–D (121–122), F–G (124–125) |
| |
| Montagnuphilone E (123) |
| Anti-inflammatory (inhibit NO production: 25.48 μM) |
| Glaziellin A (126) | The fruiting body of | Antiviral (H1N1: 230.6 μM, H3N2: 235.8 μM, H5N1: 165.4 μM) |
| Comazaphilone G (127) |
| Anti-inflammatory (inhibit NO production: 4.35 μM) |
| Comazaphilone H (128) |
| Anti-inflammatory (inhibit NO production: 40.52 μM) |
| Pinazaphilone B (129) |
| Inhibit enzyme (α-glucosidase: 28.0 μM) |
| Pinophilin G (130) |
| Antimicrobial ( |
| Talaraculone A (131) |
| Inhibit enzyme (α-glucosidase: 78.6 μM) |
| Talaraculone B (132) |
| Antimicrobial ( |
| Talaraculones C–F (133–136) |
| |
| Pleosporalone E (137) |
| Antimicrobial ( |
| Pleosporalone F (138) |
| Antimicrobial ( |
| Pleosporalone G (139) |
| Antimicrobial ( |
| Pleosporalone H (140) |
| Antimicrobial ( |
|
|
| |
| Chaetoviridin J (142) |
| Anti-tumor (inhibit NF-κB activation: 32.6% at 50 μM); anti-inflammatory (inhibit NO production: 95.4%, at 50 μM) |
| Chaetoviridin K (143) |
| Anti-tumor (inhibit NF-κB activation: 33.4% at 50 μM); anti-inflammatory (inhibit NO production: 39.4%, at 50 μM) |
| Chaephilones A–B (144–145) |
| |
| Chaephilone C (146) |
| Cytotoxic (A549: 15.7 μM, HeLa: 7.7 μM, Hep G2: 20.2 μM); antimicrobial ( |
| Nigbeauvin A (147) |
| Antimicrobial ( |
| Nigbeauvin B (148) |
| Anti-inflammatory (inhibit NO production: 39%, at 50 μM) |
| Nigbeauvins C–E (149–151) |
| |
| Nigirpexins A–C (152–154) |
| |
| Nigirpexin D (155) |
| Antimicrobial ( |
| Isonigirpexin C (156) |
| |
| Dechloroisochromophilone II (157) |
| |
|
|
| Cytotoxic (NCl-H187: 6.2 μg mL−1, KB: 6.9 μg mL−1, MCF-7: 10.6 μg mL−1) |
| 159 |
| Cytotoxic (MDA-MB-435: 24.62 μg mL−1, HepG2: 17.92 μg mL−1, HCT-116: 11.09 μg mL−1, A549: 16.63 μg mL−1) |
| Hypocrellone A (160) |
| |
| Eupenicilazaphilone A (161) |
| Cytotoxic (MCF-7: 49.95 μM) |
| Eupenicilazaphilone B (162) |
| Cytotoxic (MCF-7: 40.71 μM, A549: 63.32 μM) |
| Eupenicilazaphilone C (163) |
| Cytotoxic (MCF-7: 36.88 μM, A549: 43.96 μM) |
| Geumsanols A–B (164–165), D–E (167–168) |
| |
| Geumsanol C (166) |
| Cytotoxic (HL-60: 88.9 μM) |
| Penidioxolanes A–B (169–170) |
| |
| Penicilazaphilone C (171) |
| Cytotoxic (B-16: 0.065 mM, SGC7901: 0.720 mM); antimicrobial ( |
| Penicilazaphilones D–E (172–173) |
| |
| Sclerketide B (174) |
| Anti-inflammatory (inhibit NO production: 3.4 μM) |
| Helicusin E (175) |
| |
| Isochromophilone XI (176) |
| Antimicrobial ( |
| Bromophilone A (177) |
| Cytotoxic (L5178Y: 13.9 μM, A2780: 37 μM) |
| Bromophilone B (178) |
| Cytotoxic (L5178Y: 8.9 μM, A2780: 2.7 μM) |
| Isochromophilonol (179) |
| Cytotoxic (KB: 9.63 μg mL−1, NCI-H187: 27.18 μg mL−1) |
| Ochrephilonol (180) |
| Cytotoxic (KB: 30.2 μg mL−1) |
| Isochromophilone A (181) |
| Cytotoxic (ACHN: 27 μM, 786-O: 34 μM, OS-RC-2: 45 μM) |
| Isochromophilones B–C (182–183) |
| |
| Isochromophilone D (184) |
| Cytotoxic (786-O: 38 μM, OS-RC-2: 44 μM) |
| Isochromophilone E (185) |
| Cytotoxic (ACHN: 14 μM, 786-O: 8.9 μM, OS-RC-2: 13 μM) |
| Isochromophilone F (186) |
| Cytotoxic (ACHN: 13 μM, 786-O: 10 μM, OS-RC-2: 38 μM) |
| Sclerotiorins A–C (187–189) |
| |
| Cohaerin G (190) |
| Antimicrobial ( |
| Cohaerin H (191) |
| Cytotoxic (L929: 4.9 μg mL−1) |
| Cohaerin I (192) |
| Cytotoxic (L929: 0.4 μg mL−1); antimicrobial ( |
| Cohaerin K (193) |
| Antimicrobial ( |
| Minutellin A (194) |
| Cytotoxic (L929: 5.1 μg mL−1, KB3.1: 5.3 μg mL−1); antimicrobial ( |
| Minutellin B (195) |
| Antimicrobial ( |
| Minutellin C (196) |
| Cytotoxic (L929: 10 μg mL−1, KB3.1: 25 μg mL−1); antimicrobial ( |
| Minutellin D (197) |
| Antimicrobial ( |
| Penicilone A (198) |
| |
| Penicilone B (199) |
| Cytotoxic (SMMC-7721: 32 μM); antimicrobial ( |
| Penicilone C (200) |
| Cytotoxic (SMMC-7721: 21 μM); antimicrobial ( |
| Penicilone D (201) |
| Cytotoxic (SMMC-7721: 27 μM); antimicrobial ( |
| Penicilone G (202) |
| Cytotoxic (SMMC-7721: 21 μM); antimicrobial ( |
| Penicilone H (203) |
| Cytotoxic (SMMC-7721: 24 μM); antimicrobial ( |
| Meliasendanin A (204) | The fruits of | Antioxidant (ABTS: 62.8 μM) |
| Pleosporalone A (205) |
| Antimicrobial ( |
| Pleosporalone B (206) |
| Antimicrobial ( |
| Pleosporalone C (207) |
| Antimicrobial ( |
| Chaetomugilide A (208) |
| Cytotoxic (HePG2: 1.7 μM);[ |
| Chaetomugilide B (209) |
| Cytotoxic (HePG2: 19.8 μM) |
| Chaetomugilide C (210) |
| Cytotoxic (HePG2: 53.4 μM)[ |
| Isochromophilone XIII (211) |
| Antimicrobial ( |
| Chaetoviridide A (212) |
| Cytotoxic (A549: 15.2 μM, HeLa: 12.3 μM, Hep G2: 3.9 μM); antimicrobial ( |
| Chaetoviridide B (213) |
| Cytotoxic (A549: 16.3 μM, HeLa: 5.6 μM, Hep G2: 18.2 μM); antimicrobial ( |
| Chaetoviridide C (214) |
| Cytotoxic (A549: 23.1 μM, HeLa: 17.7 μM, Hep G2: 22.2 μM); antimicrobial ( |
|
|
| Cytotoxic (HL-60: 10.3 μM, K562: 20.3 μM, BEL-7402: 23.9 μM) |
|
|
| |
|
|
| Cytotoxic (HL-60: 11.1 μM, K562: 11.7 μM, BEL-7402: 10.9 μM, HCT-116: 11.3 μM, HeLa: 22.1 μM, L-02: 18.2 μM, MGC-803: 6.6 μM, HO8910: 9.7 μM, SH-SY5Y: 26.5 μM, NCl-H1975: 11.2 μM, U87: 18.3 μM, MDA-MB-231: 13.2 μM) |
| Peniazaphilones A–D (218–221) |
| |
| Sclerotiorin D (222) |
| Anti-inflammatory (inhibit NO production: 2.7 μM)[ |
| Isochromophilone X (223) |
| Inhibit enzyme (PDE4: 11.7 μM) |
| Penazaphilone A (224) |
| Anti-inflammatory (inhibit NO production: 15.29 μM) |
| Penazaphilones B–D, (225–227), G (230), I (232) |
| |
| Penazaphilone E (228) |
| Anti-inflammatory (inhibit NO production: 9.34 μM) |
| Penazaphilone F (229) |
| Anti-inflammatory (inhibit NO production: 9.50 μM) |
| Penazaphilone H (231) |
| Anti-inflammatory (inhibit NO production: 7.05 μM) |
| Berkchaetorubramine (233) |
| Inhibit enzyme (caspase 1: 50 μM, MMP-3: 45 μM) |
| (6-[( |
| |
| Atrorosins A, C–I, K–N, Q–R, T, V–W, Y (235–252) |
|
Fig. 3Chemical structures of austdiol-type azaphilones (28–46).
Fig. 4Chemical structures of deflectin-type azaphilones (47–65).
Fig. 5Chemical structures of bulgarialactone-type, hydrogenated spiro-azaphilones, and O-containing Monascus pigments (66–81).
Fig. 6Chemical structures of angular lactone-type azaphilones (82–95).
Fig. 7Chemical structures of hydrogenated azaphilones (96–117).
Fig. 8Chemical structures of hydrogenated azaphilones (119–141).
Fig. 9Chemical structures of chaetoviridins and chaephilones (142–146).
Fig. 10Chemical structures of pulvilloric acid azaphilones (147–156).
Fig. 11Chemical structures of sclerotiorin-like azaphilones (157–189).
Fig. 12Chemical structures of cohaerins and related azaphilones (190–207).
Fig. 13Chemical structures of nitrogenated azaphilones (208–252).
Scheme 1Synthesis of felinone A[29] Reagents and conditions: (a) Oxone®, K2CO3, CH3CN-DMM-buffer, 98%, 87% ee, then recrystallization; (b) DIBALH, toluene; (c) Ph3PCH2CH3 Br, LHMDS THF; (d) Hg(OCOCF3)2, MeOH, then NaBH4; (e) TFA, CH2Cl2–H2O; (f) TPAP, NMO, CH2Cl2; (g) TBAF, THF.
Scheme 2Synthesis of trichoflectin, (S)-deflectin-1a, and lunatoic acid A by Pyser and his co-worker.[93] Reagents and conditions: (a) AzaH (0.2 mol%), NADPH recycling system, KPi buffer, pH 8.0; (b) AfoD (0.8 mol%), NADPH recycling system, KPi buffer, pH 8.0; (c) Et3N, mol sieves, toluene, 110 °C; (d) DMAP, toluene, 110 °C; (e) Grubbs 2nd Gen, methyl acrylate, DCM, 45 °C; (f) LiOH, THF : MeOH : H2O, r.t.
Scheme 3Synthesis of chaetoglobin A.[94] Reagents and conditions: (a) PdCl2(PPh3)2, CuI, Et2NH, DMF, 65 °C, 18 h; (b) HOAc, O2, ClPh, 0 °C, 48 h, 67% (BRSM); (c) CH2Cl2, −35 °C, 12 h; (d) AgOTf, DCE/TFA, r.t., 1.5 h; (e) IBX, Bu4NI, r.t., 18 h; (f) Ac2O, DMAP, Et3N, CH2Cl2, −78 °C, 0.5 h; (g) Ti(Oi-Pr)4, THF, 50 °C, 24 h; (h) NH4OAc, CH2Cl2, r.t., 20 h.
Scheme 4Synthesis of chaetoviridins.[95] Reagents and conditions: (a) NCS; (b) NaH/MOMCl; (c) LDA/CO2; (d) C6F5OH, EDC/DMAP; (e) n-BuLi; (f) K2CO3, EtOH; (g) DIBAL-H; (h) IBX/TFA/H2O; (i) Et3N, toluene, reflux; (j) HF/pyridine.
Scheme 5Synthesis of chlorofusin and its chromophore diastereomers.[96] Reagents and conditions: (a) AgNO3, TFA, ClCH2CH2Cl; (b) IBX, n-Bu4NI; (c) butytryl chloride pyridine, DMAP, DCM; (d) SO2Cl2, DCM; (e) aq. NaHCO3 (sat.), CH3CN, r.t.; (f) TFA : H2O (v/v = 10 : 1), (i-Pr)3SiH; (g) allyl bromide Pd(PPh3)4, KF·Al2O3, DMF; (h) K2CO3, MeOH; (i) I2, NaHCO3, n-Bu4NI, CH3CN/H2O; (j) DMP, NaHCO3, DCM; (k) NaBH3CN, CeCl3·7H2O, MeOH, r.t.; (l) Pd(Ph3)4, NDMBA, DCM, MW; (m) KF·Al2O3, DMF; (n) Pd/C, H2, THF/DMF; (o) Cbz-OSu, NaHCO3, THF/H2O; (p) TFA·H2N-octapeptide-OBn 71, EDCl, HOBt, DlEA, DCM/DMF; (q) Pd/C, H2, THF/DMF; (r) EDCl, HOAt, NaHCO3, DMF.
Scheme 6Biosynthesis of mycoleptone A.[15]
Scheme 7Biosynthesis of monasfluols A and B, MC-2 and MC-4.[46,48,98]
Scheme 8Proposed biosynthetic route to azaphilone 7.[18]
Scheme 9Postulated biogenetic pathway for penicilazaphilone E.[76]
Scheme 10Proposed biosynthesis of chaephilone B.[62]
Scheme 11Biosynthesis of acetosellin.[38]
Scheme 12Biosynthesis of chaephilone C, chaetoviridides A and B.[64]
Scheme 13Proposed biosynthesis of colletotrichones A–C, and chermesinonen B.[37]
Scheme 14Postulated biosynthesis of coniellins A, H, and I.[35]
Scheme 15Proposed biogenesis of thielavialides A–E.[40]
Scheme 16Proposed biosynthetic relationships among dothideomynones D–F.[34]
Scheme 17Proposed biosynthesis of cochliodone A and chaetoglobin A.[99]
Scheme 18Biosynthesis of 6′′-hydroxy-(R)-mitorubrinic acid, purpurquinone D (−)-mitorubrinic acid, (−)-mitorubrin, and purpurquinone A.[53]
Scheme 19Possible biosynthesis of cazisochromene, chaetoviridin A, and chaetomugilin A.[100]
Scheme 20Plausible biosynthesis of citrifurans A–D.[7]
Scheme 21Postulated biosynthesis of sclerketides B and C.[77]
Scheme 22Plausible biosynthesis of bromophilones A and B.[79]
Fig. 14Species distribution of azaphilones from fungal sources.
Fig. 15The percent of types of bioactivity out of all bioactive azaphilones (A)/all azaphilones (B); numbers of recently reported new azaphilones and related articles published in different journals (2013–2019) (C).